Biodexa Pharmaceuticals - צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים BDRX

Biodexa Pharmaceuticals (BDRX) maintains a protected patent margin based on the development of complex generics for brain treatment. The current YoY TTM revenue growth rate, which the GURU.Markets service illustrates in this chart, is accompanied by the value 0.00, characterizing this valuation parameter. However, the company allocates resources to laboratories without scaling, although its unique drug delivery methods help combat rare cancers.
Biodexa Pharmaceuticals (BDRX) - פילוחי מדדים ודוחות פיננסיים

Biodexa Pharmaceuticals focuses on developing advanced drug delivery systems across the blood-brain barrier for the therapy of rare brain oncopathologies. Analyzing the rolling 12-month sales growth relative to the previous year allows for an assessment of the net annual revenue increase, which helps investors distinguish short-term volatility from sustainable business scaling and minimize portfolio drawdown risks.